We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Private drug plans competing for business under the Medicare prescription drug benefit will be able to negotiate drug price savings that are at least equal to what the government could achieve through direct price negotiations, according to the head of the Centers for Medicare & Medicaid Services (CMS).
A wave of consolidations in the generic drug market due to increasing competition among generic drugmakers may occur during the next few years, according to an industry analyst.
Increasing competition in the generic drug market may drive a wave of consolidations among generic drugmakers in the next few years, according to an industry analyst.
Forest Laboratories will post summaries of clinical trials it sponsors on a publicly available online registry to resolve an investigation by the New York attorney general into whether the company concealed information about the safety and efficacy of its antidepressants.
GlaxoSmithKline (GSK) has agreed to pay the state of New York $2.5 million to settle litigation related to the disclosure of data on the use of Paxil in children and adolescents with depression.
Barr Pharmaceuticals has received a license from drugmaker Cephalon to market a generic version of Cephalon’s cancer pain treatment Actiq (oral transmucosal fentanyl citrate).
Alpharma and OTC drugmaker Perrigo will pay the FTC a combined $6.25 million to settle a complaint that alleged an agreement between the two companies limited competition for OTC pediatric liquid ibuprofen and drove up prices.
The two largest generic firms have increased their footprints on both sides of the Atlantic, with Teva acquiring a generic drugmaker in Italy and Sandoz buying a generic injectables firm in Canada.
Generic pharmaceutical manufacturer Alpharma and OTC drugmaker Perrigo will pay the FTC a combined $6.25 million to settle a complaint that alleged an agreement between the two companies limited competition for OTC pediatric liquid ibuprofen, drove up prices and violated federal law.